Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > REGULATORY
REGULATORY
- AMED Looks to Bridge “Valley of Death” with Pre-Orphan Designation Scheme
November 20, 2015
- Pharmas Present 9 Requests on Drug Pricing, Tax to LDP Study Group
November 20, 2015
- MHLW Panel Approves Additional Shipment of Kaketsuken’s Venilon, Novact
November 20, 2015
- Viekirax Price, Peak Sales Forecast Called into Question
November 19, 2015
- Chuikyo OKs Viekirax, Other Drugs for NHI Price Listing on Nov. 26
November 19, 2015
- Chuikyo Approves Listing of Temcell and HeartSheet, First Two Regenerative Medicine Products
November 19, 2015
- AbbVie’s Hep C Drug Viekirax Priced at 53,000 Yen Daily vs. Harvoni’s 80,000 Yen
November 18, 2015
- MHLW Cautions against Reference Pricing, Says Impact on Pharmas Would Be Huge
November 18, 2015
- Research-Driven Drug Makers Should Collaborate with Startups, Academia: MHLW Official
November 17, 2015
- PAFSC’s 2nd Committee to Review Lung Cancer Indication for Opdivo on Nov. 30
November 17, 2015
- PAFSC 1st Committee to Discuss Japan’s First PCSK9 Inhibitor on Nov. 27
November 16, 2015
- Novartis Japan Told to Improve Business over Delayed Reporting of Nearly 5,500 ADRs
November 16, 2015
- Business Improvement Order Issued to Novartis Japan
November 13, 2015
- “We Want to Avoid a Market Price Survey” Ahead of NHI Price Revision in FY2017: MHLW Official
November 13, 2015
- Re-Pricing of “Huge Seller” Drugs Seen Inevitable Despite Industry Opposition
November 12, 2015
- Chuikyo Leaning toward Continuing Innovation Premium for On-Patent Drugs
November 12, 2015
- Chuikyo Subcommittee Broadly OKs Price Maintenance Rule for Essential Drugs
November 12, 2015
- Financial Impact of New Drug Development Premium in FY2014 Revision Totaled 79 Billion Yen
November 12, 2015
- MHLW Floats Incentive for Hospital-Pharmacy Collaboration to Reduce Drugs Prescribed to Elderly
November 10, 2015
- JMA Reps Express Opposition to Expansion of Divided Dispensing of Long-Term Prescriptions at Chuikyo
November 10, 2015
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…